Get started
Author

Claudia Fromond

Observed names: C. Fromond, Claudia Z-A Fromond
ORCID: 0000-0003-0885-9381
Observed ORCID: 0000-0003-0885-9381
OpenAlex ID: A5086798786
Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.
2021 · Stéphane Champiat, Philippe A. Cassier, et al. · Journal of Clinical Oncology · 28
983P Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor
2021 · N. Kotecki, S. Champiat, et al. · Annals of Oncology · 14
First-in-Human Study in Healthy Subjects with the Noncytotoxic Monoclonal Antibody OSE-127, a Strict Antagonist of IL-7Rα
2023 · Nicolas Poirier, Irène Baccelli, et al. · The Journal of Immunology · 13
Abstract A129: Generation of YAP-TEAD Protein-Protein Interaction (PPI) inhibitors for the treatment of cancer
2015 · Anne Soude, Martine Barth, et al. · Molecular Cancer Therapeutics · 4
Abstract 2200: A rational approach for discovery of inhibitors of YAP-TEAD interaction
2015 · Claudia Fromond, Laurent Chene, et al. · Cancer Research · 3
Abstract 2129: Predictive response biomarkers from Phase I clinical trial of a SIRPalpha inhibitor BI765063, stand-alone and in combination with ezabenlimab, a PD1 inhibitor, in patients with advanced solid tumors
2023 · Stéphane Champiat, Philippe A. Cassier, et al. · Cancer Research · 2
557 A rational approach for discovery of inhibitors of YAP-TEAD interaction
2014 · L. Chene, A. Soude, et al. · European Journal of Cancer · 2
Abstract 894: Discovery of YAP-TEAD protein-protein interaction (PPI) inhibitors for cancer therapy
2016 · Anne Soude, Martine Barth, et al. · Cancer Research · 1
Abstract 1993: Biomarker analyses from the Phase I clinical trial of the first-in-class SIRPa immune checkpoint inhibitor BI765063 in patients with advanced solid tumors
2022 · Stephane Champiat, Philippe A. Cassier, et al. · Cancer Research
366 Combined exploratory immunophenotyping and transcriptomic tumor analysis in patients treated with OSE2101 vaccine in HLA-A2+ advanced non-small cell lung cancer (NSCLC) from the ATALANTE-1 trial
2021 · Santiago Viteri, Werner Hilgers, et al. · Journal for ImmunoTherapy of Cancer
PDF
Abstract 4524: A rational approach for the discovery of inhibitors of NSD2 for the treatment of multiple myeloma
2016 · Claudia Fromond, Xavier Espanel, et al. · Cancer Research
Abstract 99: Identification of G9a inhibitors by AlphaLisa™ technology and hit confirmation using MT-Glo™
2015 · Claudia Fromond, Xavier Espanel, et al. · Cancer Research
Abstract 105: A rational approach for the discovery of inhibitors of NSD2 for the treatment of cancer
2015 · Claudia Fromond, Xavier Espanel, et al. · Cancer Research
594 Identification of novel EZH2 inhibitor scaffolds
2014 · X. Espanel, L. Chene, et al. · European Journal of Cancer
Works count: 14
Citation count: 67
H-index: 4
I10-index: 3
Year
Topic
Type